» Articles » PMID: 31229481

Optimization of Transbronchial Cryobiopsy in Lung Transplant Recipients

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2019 Jun 24
PMID 31229481
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies suggest that transbronchial lung biopsy using a cryoprobe is superior to transbronchial lung biopsy using forceps for evaluating lung grafts, although the technique can be associated an increase in complications. Because cryoprobe experience is limited, assessment of a greater number of cases is warranted. This prospective study evaluates the diagnostic yield, complications, and risk factors associated with the cryoprobe technique.

Methods: From April 2013 to April 2016, 321 consecutive cryoprobe transbronchial biopsies were indicated in single or bilateral lung transplant patients with acute or chronic clinical lung injury or in asymptomatic patients before hospital discharge after lung transplantation.

Results: With a mean of 4.32 lung parenchyma specimens per procedure, adequate alveolar lung parenchyma was obtained in 96.6% (84.27 ± 44.14 mm) of cases. Obtaining at least 4 samples increased the histological diagnostic certainty (P < .001). Moderate to severe bleeding was observed in 7.48% of patients and was significantly more frequent in patients with unilateral transplantation (odds ratio, 0.10; 95% confidence interval, 0.02-0.30; P < .001) and in those with high blood pressure during scanning (odds ratio, 0.31; 95% confidence interval, 0.12-0.86; P = .019). Pneumothorax was observed in 7.7% of the patients, but only 3.7% of these patients required pleural drainage.

Conclusions: Obtaining 4 or more cryobiopsy samples is valuable and safe for lung allograft monitoring. Being a recipient of a unilateral lung transplant or having arterial hypertension during bronchoscopy seem to be risk factors associated with increased bleeding.

Citing Articles

Transition from Transbronchial Forceps to Cryobiopsy After Lung Transplantation: A Single-Centre Experience.

Tosi D, Brivio M, Franzi S, Palleschi A, Bonitta G, Lopez G Life (Basel). 2024; 14(11).

PMID: 39598272 PMC: 11595684. DOI: 10.3390/life14111474.


PD-1 expression in transbronchial biopsies of lung transplant recipients is a possible early predictor of rejection.

Righi I, Vaira V, Morlacchi L, Croci G, Rossetti V, Blasi F Front Immunol. 2023; 13:1024021.

PMID: 36703976 PMC: 9871480. DOI: 10.3389/fimmu.2022.1024021.


Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant.

Rosenheck J, Ross D, Botros M, Wong A, Sternberg J, Chen Y Transplant Direct. 2022; 8(4):e1317.

PMID: 35372675 PMC: 8963832. DOI: 10.1097/TXD.0000000000001317.


Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19.

Culebras M, Loor K, Sansano I, Persiva O, Clofent D, Polverino E Chest. 2021; 161(3):647-650.

PMID: 34582842 PMC: 8464080. DOI: 10.1016/j.chest.2021.09.016.


Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation.

Khush K, De Vlaminck I, Luikart H, Ross D, Nicolls M ERJ Open Res. 2021; 7(1).

PMID: 33532456 PMC: 7836440. DOI: 10.1183/23120541.00462-2020.